Member Info for inanaco

Michaelhighbar

I don't think it would help at this stage, you can actually compare the trial with that genexine GX188 trial with Merck not huge patient numbers .. so i am happy that its done inhouse, better to sell the data ...than the principle behind the synergy

Cars its not the same as TCR ..

Ray

Also, are the actions of the TILs suppressed by TRegs meaning that the addition of a CI may be helpful?

only trial results would allow discussions of how its used and with what ..

I would be careful about making definitive statements like that Bermuda ... just simply because we do not know the Efficacy level yet .

Its a personal treatment .... completely different to Scancells

a previous posts of yours gave the impression that you did not understand the science behind SCIB1 and indeed the effect of Keytruda ..

i suggest you wait until this current trial by Achillies Therapeutics is over, then the follow up trial will probably be with a check point like keytruda

its all baby steps unless of course your treating a pandemic

that really is good new ... thanks

its grim news ...

yes but the flip switch includes "an upgrade"

I cannot ramp like that .. i am not Emily Maitlis lol

once we are in trial .. we can see the results very quickly ...

because the ""The immunosuppressive tumour environment may inhibit these responses""

and hopefully the invigorated Modi1 T cells can break that tolerance ... it also opens the possibility of using check points to target that environment in support ....

so basically what the body has done is down regulated the CD4 T cells to """lower frequency and avidity"""

scancell is going to increase frequency of them and give the t cells High Avidity and High inflammatory signaling using Amplivant to polarize the T cells to Th1

hope that helps

• Citrullinated peptides induce potent anti-tumour immunity with no
evidence of associated toxicity and will shortly enter the clinic

tick tock

far more advanced ...

When the T cell repertoire is subject to self-tolerance, the induction of epitope-specific
CD4+ T cell responses is much more limited and resulting responses are
of lower frequency and avidity. Citrullinated self-epitopes may be an
exception as CD4+ T cells to these epitopes are positively selected in
the thymus and may be crucial in detecting stressed cells. The immunosuppressive tumour environment may inhibit these responses but
vaccination may reinvigorate them.

cant wait ... come on lets get this into trial ..

look at the date

http://www.koreabiomed.com/news/articleView.html?idxno=8103

?

here is Scancells testing with Adjuvants

https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/poster-1-conference-mainz-sept-17.pdf

take it with a pinch of salt ... you don't just put vaccines and adjuvants together without serious testing ..

that would occur in the Platform stage or after you have tested the vaccine in humans and found it did not produce the desired profile .. ie back to drawing board ...

GSK is probably banking a bit on that ...

worse case its stock pile goes into next years flu jab ...

Bermuda may remember this ... my dislike of Inovio .. but i highlighted one vaccine Genexine

At AACR, Hur and colleagues presented the preliminary efficacy and safety results of a phase 2 study of pembrolizumab and GX-188E for patients with HPV 16-positive and/or HPV 18-positive advanced cervical cancer who have failed all available standard-of-care therapies. The investigators reported an impressive overall response rate of 45.5% compared with a 14.3% historical response to single-agent pembrolizumab, without new safety signals. This suggests great synergy between GX-188E and pembrolizumab and, in contrast to pembrolizumab monotherapy, responses were independent of PD-L1 expression.

so back to Scancell ................. SCIB1 and Keytruda (pembrolizumab)

The combo also worked in PD-L1 negative patients who did not respond to the Keytruda monotherapy. The ORR in PD-L1 negative patients recorded 16.7 percent.

https://www.healio.com/hematology-oncology/gynecologic-cancer/news/online/%7B41d6b98b-b5bf-4d2b-b029-77c5bbbb4ced%7D/addition-of-gx-188e-to-pembrolizumab-improves-response-rate-in-advanced-cervical-cancer

http://www.koreabiomed.com/news/articleView.html?idxno=8103

THIS is why Scancell is such a great investment ....

once you understand that the way you engage the immune system for a vaccine is absolutely critical if you want a good result

http://www.genexine.com/m22.php

cross presentation . ? no

the problem at this level ... its not salesman that close deals if you look at some of the top execs they are scientists ..

collaborations that might lead to deals are done by the scientists ..

CRUK investment all down to the science

you have to take in the whole 10 years of immunbody development and the way the market has changed with other approvals and failures to understand how we have arrived here today
its not a case of Scancell sitting on the fence
Its a case that Scancell has adapted and developed immunobody with the knowledge that other areas ie the check points have developed ... and the way it slots back in to achieve commercial advantage

It had commercial advantage in 2013 ............

but failure after failure of big pharma to build a cancer vaccine soured the market

you have to consider that Keytruda was nearly Binned ....

its only if you can look at the entire picture do you see that actually we are still in a prime position ...

but employing staff to match Big Pharma is not going to come cheap ....

CEO Company Total pay
BRENTON L SAUNDERS ALLERGAN $32,827,626
ALEX GORSKY JOHNSON & JOHNSON $29,802,564
IAN C READ PFIZER INC $27,913,775
LEONARD S SCHLEIFER REGENERON PHARMACEUTICALS $26,508,058

Dracula ....

You clearly do not have a Clue what Scancell is doing ..

"""Then being tried with other compounds when I thought with the results It received.....would be a Very worthy stand alone compound.""""

Done that all my life mate ....... ended up with more buildings than i can count on my fingers ... but that takes on a significance later in life as debt falls and inflation creeps up ... if i was to trade property maybe i could have made more money .... who knows

so easy to suggest after an event than before ... maybe i should have sold all in 2006/7 then bought back in 2010 ... but what i do know the property value's in 2006 have been surpassed in 2018/19 ... what happens next ... no idea, but now, because i held i have the QTY of property to ride the storm, and the right property in the storm .. (no retail)

What you maybe have not understood from my posts ... my expectations have risen not fallen ..